DAPA-HF Response Predictor Calculator

Clinical calculation support · Verify results before clinical use

Patient profile

Enter baseline characteristics from the clinical assessment. The form summarizes the profile; it does not calculate an individualized treatment-response probability.

Not a validated prediction model
DAPA-HF enrolled patients with LVEF ≤40%.
Enter NT-proBNP if available; otherwise enter BNP. The two assays are not interchangeable.
Reset form

Clinical context

The DAPA-HF randomized trial evaluated dapagliflozin 10 mg once daily in patients with symptomatic heart failure and LVEF ≤40%, on recommended background therapy. Over a median 18.2 months, the primary composite of worsening heart failure or cardiovascular death occurred in 16.3% of the dapagliflozin group and 21.2% of the placebo group (hazard ratio 0.74; 95% CI 0.65–0.85).

What this tool can and cannot tell you

  • It can collect and display selected baseline variables relevant to the clinical profile.
  • It does not reproduce a validated DAPA-HF treatment-effect model or estimate an individual probability of response.
  • Baseline risk and absolute benefit are not the same as a validated prediction of differential treatment response.
  • Diabetes status alone should not determine whether an otherwise eligible patient is considered for dapagliflozin.

Practical use

Use the profile as a documentation aid only. Treatment decisions should follow current heart-failure guidelines and product information, with assessment of renal function, blood pressure, volume status, concomitant therapy, and patient-specific contraindications or precautions.

References

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995–2008. doi:10.1056/NEJMoa1911303. PMID: 31535829.
Docherty KF, Simpson J, Jhund PS, et al. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. JACC Heart Fail. 2022;10(2):104–118. doi:10.1016/j.jchf.2021.09.002. PMID: 35115084.
Clinical disclaimer: This page is an educational profile tool, not a validated clinical prediction rule, prescribing recommendation, or substitute for clinician judgment. It does not calculate individualized treatment benefit. Verify eligibility and prescribing decisions against current guidelines and official product information.